Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females
ISRN Obstetrics and Gynecology · 02.11.2011 · 2011 · 1-20
DOI: 10.5402/2011/457204 ↗Kurz gefasst
Fachartikel in der Zeitschrift ISRN Obstetrics and Gynecology, erschienen am 02.11.2011. Verfasst von Diane M Harper und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center of Excellence, Women's Health, University of Missouri-Kansas City School of Medicine, 7900 Lee's Summit Road, Kansas City, MO 64139, USA. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
Nearly a half a million women throughout the world develop cervical cancer every year Parkin and Bray (“Chapter 2. The burden of HPVrelated cancers,” Vaccine, vol. 24, no. 3, pp. S11–S25, 2006); 80% of these women are in countries without a quality-assured cytology screening program. It is in this setting that Cervarix could reduce the incidence of cervical cancer to about 9.5/100,000 women. New evidence indicates that this might be able to be accomplished with a single dose of Cervarix, a great advantage to public health implementation programs Kreimer et al. (“Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine, The Journal of the National Cancer Institute , vol. 103, no. 19, pp. 1444–1451, 2011). In countries with screening programs, adenocarcinoma is the most difficult to detect and treat with later-stage presentation and higher mortality Smith et al. (“The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States—a 24-year population-based study,” Gynecologic Oncology , vol. 78, no. 2, pp. 97–105, 2000) and Gunnell et al. (“A longitudinal Swedish study on screening for squamous cell carcinoma and adenocarcinoma: evidence of effectiveness and overtreatment,” Cancer Epidemiology Biomarkers and Prevention , vol. 16, no. 12, pp. 2641–2648, 2007). With additional cross-protection to HPV 31, 33, and 45 and protection against HPV 16 and 18 lasting at least 9.4 years, Cervarix may reduce adenocarcinomas in screened populations by more than 90%. This paper will detail the evidence about the efficacy, immunogenicity, and safety of Cervarix in the studied populations contrasting public health goals with individual health options.
Autor:innen und Institutionen
- Center of Excellence, Women's Health, University of Missouri-Kansas City School of Medicine, 7900 Lee's Summit Road, Kansas City, MO 64139, USA.
Zitieren
APA
Harper, D. M., & Vierthaler, S. L. (2011). Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females. ISRN Obstetrics and Gynecology, 2011, 1-20. https://doi.org/10.5402/2011/457204
Vancouver
Harper DM, Vierthaler SL. Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females. ISRN Obstetrics and Gynecology. 2011;2011:1-20. doi:10.5402/2011/457204
BibTeX
@article{Harper2011,
author = {Harper, Diane M and Vierthaler, Stephen L},
title = {Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females},
journal = {ISRN Obstetrics and Gynecology},
year = {2011},
volume = {2011},
pages = {1--20},
doi = {10.5402/2011/457204}
}
EUVIMED